In the studies by Bouchi et al. and Sato et al., the SGLT-2 inhibitors Dapagliflozin and Luseogliflozin both improved systemic inflammation and were used for EFT, thereby reducing the EFT volume of DM patients and thus reducing the risk of cardiovascular disease [60, 61]. Here, SLC5A2 is linked to cardiovascular disorder.